Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to *Staphylococcus aureus*

Pierre Vaudaux*, Patrice Francois, Carmelo Bisognano, Dongmei Li, Daniel P. Lew and Jacques Schrenzel

Division of Infectious Diseases, Geneva University Hospital, CH-1211 Geneva 14, Switzerland

Received 8 January 2003; returned 14 February 2003; revised 4 March 2003; accepted 6 April 2003

The therapeutic activity of daptomycin was compared with that of vancomycin in a rat model of subcutaneously implanted tissue cages chronically infected with strain Rev1, a spontaneous methicillin-susceptible revertant of the methicillin-resistant *Staphylococcus aureus* strain MRGR3, showing equivalent virulence to its parent. The MIC and MBC of daptomycin (in Mueller–Hinton broth supplemented with 50 mg/L Ca²⁺) or vancomycin for strain Rev1 were 1–2 and 2–4 or 1 and 2 mg/L, respectively. In vitro elimination of strain Rev1 in the presence of 50% tissue cage fluid was more rapid with daptomycin 4 mg/L compared with vancomycin. After 2 weeks of infection, viable counts of strain Rev1 averaged 6.49 log₁₀ cfu/mL of tissue cage fluid (n = 87). Intraperitoneal administration of daptomycin 30 mg/kg once daily, or vancomycin 50 mg/kg twice daily, produced antibiotic levels continuously above MBC. After 7 days of therapy with daptomycin or vancomycin, mean ± S.E.M. counts of Rev1 decreased (P < 0.05) by 1.11 ± 0.25 (n = 28) or 0.80 ± 0.31 (n = 35) log₁₀ cfu/mL, respectively, compared with cages of untreated animals, but were not significantly different from each other. In daptomycin-treated rats, three cages yielded subpopulations with reduced susceptibility to daptomycin.

In conclusion, a low dose regimen of daptomycin was at least equivalent to vancomycin against chronic foreign body infections due to *S. aureus*. Drug dosage should be adapted to obtain inflammatory fluid levels of daptomycin minimizing emergence of resistant subpopulations.

Keywords: Gram-positive bacteria, chronic infections, antimicrobial agents

Introduction

Prosthetic device infections, in particular those resulting from *Staphylococcus aureus*, are notoriously difficult to treat, and microbiol eradication frequently requires the removal of infected materials. Recent clinical studies using combinations of fluoroquinolones and rifampcin yielded promising results for the treatment of orthopaedic prosthetic *S. aureus* infections without prosthesis removal.¹–⁴ Unfortunately, a vast majority of mexitilin-resistant strains of *S. aureus* (MRSA) are also resistant to virtually all fluoroquinolones,⁵ which severely limits the therapeutic armamentarium for the treatment of foreign body infections. Thus, glycopeptide therapy with vancomycin or teicoplanin, alone or in combination with rifampcin,⁶–⁸ frequently remains the only available therapy for severe MRSA infections, but does not always prevent the emergence of rifampcin-resistant mutants.⁹ An additional concern is the recent discovery of glycopeptide-intermediate or -resistant strains of *S. aureus* in several parts of the world.¹⁰–¹⁴ The increasing use of glycopeptides for therapy of Gram-positive infections may further promote the emergence of more highly glycopeptide-resistant strains.¹⁵,¹⁶

Daptomycin is a lipopeptide antibiotic with potent *in vitro* bactericidal activity against a wide range of Gram-positive pathogens, including antibiotic-resistant *staphylococci*.¹⁷–²⁰ The mechanism of action of daptomycin is not fully understood, but seems to be distinct from that of major cell wall-active agents, such as β-lactams and glycopeptides. Daptomycin binds in a calcium-dependent manner to Gram-positive cytoplasmic membranes,²¹,²² and disrupts membrane function, dissipating membrane potential and inhibiting macromolecular biosynthesis. Daptomycin is uniformly potent against *S. aureus* clinical isolates in large surveillance studies.²³–²⁷ The in vivo activity of daptomycin is currently being evaluated in both therapeutic trials and experimental models.²⁸ Optimization of daptomycin pharmacokinetics and pharmacodynamics against severe *S. aureus* infections requires maximum efficacy and safety, and the maintenance of bactericidal levels in deep-seated compartments.¹⁷,¹⁹,³³

*Corresponding author. Tel: +41-22-37-29-826. Fax: +41-22-37-29-830; E-mail: pierre.vaudaux@hcuge.ch

© 2003 The British Society for Antimicrobial Chemotherapy
We previously showed the usefulness of a rat tissue cage model of \textit{S. aureus} chronic foreign body infections for evaluating various categories of antimicrobial agents such as vancomycin, teicoplanin, imipenem, and several fluoroquinolones including fleroxacin, sparfloxacin, temafloxacin, ciprofloxacin, levofloxacin and trovafloxacin, alone or in combination with rifampicin.

In this study, we evaluate the efficacy of a once-daily dosing of daptomycin compared with a twice-a-day regimen of vancomycin in the therapy of experimental chronic foreign body infections due to \textit{S. aureus}.

Materials and methods

\textbf{Bacterial strains}

Strain Rev1 is a spontaneous methicillin-susceptible revertant of MRSA strain MGR3, a clinical isolate from a patient with catheter-related sepsis. Strain Rev1 was found to be as virulent in the rat model of chronic \textit{S. aureus} tissue cage infection as its MRSA parental strain, except for the loss of the methicillin resistance element, strain Rev1 exhibits an antibiotic resistance pattern identical to its MRSA parent, including resistance to penicillin, gentamicin, chloramphenicol, erythromycin, tetracycline and polymyxin B, but susceptibility to clindamycin, rifampicin and all fluoroquinolones.

\textbf{Antimicrobial agents}

For \textit{in vitro} studies, daptomycin (Cubist Pharmaceutical, Inc., Lexington, MA, USA) was solubilized in distilled water at a concentration of 1 mg/mL and further diluted in saline. For \textit{in vivo} studies, daptomycin was solubilized in saline at a concentration of 7.5 mg/mL. Commercially available vancomycin hydrochloride (Lilly, Giessen, Germany) was suspended as recommended by the manufacturer.

\textbf{In vitro studies}

MICs of daptomycin and vancomycin for strain Rev1 were determined in cation-adjusted Mueller–Hinton broth (CAMHB) containing 20–25 mg/L Ca\textsuperscript{2+} and 10–12.5 mg/L Mg\textsuperscript{2+} by the standard broth macrodilution method, with an average inoculum of 10\textsuperscript{6} cfu/mL, as described by the NCCLS. For daptomycin MIC, CAMHB was supplemented with additional calcium to a physiological concentration of 50 mg/L Ca\textsuperscript{2+} (CSMHB).

To screen for the possible carryover effects of each antibiotic during the MBC determinations, 10-fold diluted portions on MHA after 0, 1, 3, 6 and 24 h of incubation. Plates were incubated for 48 h at 37°C. The detection limit was 2 log\textsubscript{10} cfu/mL of tissue cage fluid. The differences in cfu counts between days 1 and 8 were determined and expressed as ∆log\textsubscript{10} cfu/mL. The means ± S.E.M. of ∆log\textsubscript{10} cfu/mL of three independent determinations were analysed for significant differences by unpaired t-tests. Data were considered significant when P < 0.05 using two-tailed significance levels.

\textbf{Treatment of chronic tissue cage infections}

Experiments involving rats were approved by the Ethics Committee of the Faculty of Medicine, University of Geneva, and by the Veterinary Office of the State of Geneva. Four tissue cages were implanted subcutaneously, as described previously, in Wistar rats that had been anaesthetized with an intraperitoneal injection of a mixture of ketamine (90 mg/kg) and xylazine (5 mg/kg). At 3 weeks post-implantation, tissue cage fluid was aspirated and checked for sterility. To establish a chronic \textit{S. aureus} infection, tissue cages were inoculated with 0.1 mL of saline containing 0.2 × 10\textsuperscript{6} to 2 × 10\textsuperscript{6} cfu of a log-phase culture of strain Rev1. Two weeks later, all tissue cages containing more than 10\textsuperscript{5} cfu/mL of fluid were included in the therapeutic protocols.

Rats infected with strain Rev1 were randomized to receive (by the intraperitoneal route for 7 days) either a once-a-day regimen of daptomycin (30 mg/kg) or a twice-a-day regimen of vancomycin (50 mg/kg), or were left untreated.

At 12 h after the last injection of vancomycin or 24 h after the last injection of daptomycin, quantitative cultures of 10-fold serially diluted tissue cage fluids were performed on MHA. To optimize the yield of viable bacteria, tissue cage fluids were sonicated briefly (60 W, 1 min) to disrupt the biofilm and phagocytic cells before the serial dilutions and plating. Plates were incubated for 24–48 h at 37°C. The detection limit was 2 log\textsubscript{10} cfu/mL of tissue cage fluid. The differences in cfu counts between days 1 and 8 were determined and expressed as ∆log\textsubscript{10} cfu/mL. For each treatment group, results were expressed as means ± S.E.M. Comparison of bacterial counts in the different groups was performed by one-way analysis of variance and t-tests corrected for multiple groups. Data were considered significant when P < 0.05 using two-tailed significance levels.

\textbf{Resistance to antimicrobial agents}

In initial experiments, the bacteria recovered from cage fluids on day 8 of therapy were screened for the emergence of resistance to daptomycin on MHA. Samples (of 10\textsuperscript{6} cfu/mL) were plated onto MHA containing daptomycin 4 mg/L. Plates were incubated for 48 h at 37°C. The detection limit was 1 log\textsubscript{10} cfu/mL of tissue cage fluid.

Further analysis of subpopulations that grew on the daptomycin-containing agar from some tissue cages was first performed on colonies.
recovered from the primary antibiotic-containing plates. The identification of representative individual colonies as S. aureus was assessed by standard microbiological procedures, and their clonal relationship with strain Rev1 confirmed by pulse-field gel electrophoresis (PFGE). The overall antimicrobial susceptibility of 10 colonies isolated from each primary daptomycin-containing plate was compared with strain Rev1 by disc diffusion using MHA, according to NCCLS recommendations. The antibiotics tested were daptomycin (30 µg paper discs provided by Cubist) and 15 commercially available discs containing penicillin, oxacillin, gentamicin, norfloxacin, ciprofloxacin, trovafloxacin, clindamycin, erythromycin, fusidic acid, co-trimoxazole, fosfomycin, rifampicin, vancomycin, teicoplanin or mupirocin. Three additional colonies from each daptomycin-containing plate were tested separately for increased daptomycin MICs, compared with strain Rev1, by a standard broth microdilution test, as recommended by NCCLS, using either CAMHB or CSMBH. Finally, the stability of the daptomycin MICs was checked by agar dilution, broth microdilution and macrodilution assays performed on individual colonies that had been stored in skim milk for 6–12 months at −70°C.

Pharmacokinetics of antimicrobial agents

The pharmacokinetic properties of vancomycin in rat tissue cage fluid have been estimated previously. In rats treated with daptomycin, its pharmacokinetic levels in tissue cage fluids were determined at various time intervals (0, 2, 4, 6, 12 and 24 h) on days 4 and 7 of therapy. Similarly, blood levels of rats treated with daptomycin were also determined at various time intervals (0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h) after single-dose intraperitoneal administration of the antimicrobial agent. The blood was collected by cardiac puncture into heparinized tubes. Plasma was collected by centrifugation and samples were stored at −20°C until analysis.

Daptomycin analytical assay

Daptomycin was detected using an internal standard of ethylparaben, and was isolated by protein precipitation with methanol, followed by HPLC. The mobile phase consisted of 90% mobile phase A (acetonitrile: 0.5% NH₄H₂PO₄ 34:66, v/v) and 10% mobile phase B (acetonitrile: 0.5% NH₄H₂PO₄ 20:80, v/v) at a flow rate of 1.5 mL/min. Serum drug concentrations were determined by reverse-phase HPLC using a Metachem Hypersil C8 analytical column and a Waters Xterra RP18 guard column (ANSYS Technologies, Inc., Lake Forest, CA, USA). At a flow rate of 1.5 mL/min, daptomycin shows a retention time of 141 nm. Samples were analysed at 214 nm. The detection of daptomycin concentrations in rat plasma was linear across the range of 7.5–400 mg/L. This method has been validated for daptomycin over the concentration range of 3–500 mg/L, with a lower limit of quantification equal to the lowest calibration level of 3 mg/L.

The concentrations of daptomycin in rat tissue cage fluid were estimated by a previously described microbiological assay, except for the use of Antibiogram medium 11 and Sarcina lutea as the test strain. To avoid a potential bias due to protein binding, all tissue cage fluids were diluted with one volume of PBS. Thus, tissue cage fluid protein concentrations of samples were equivalent to those of daptomycin standards prepared in PBS supplemented with 50% of sterile pooled tissue cage fluid. Under these experimental conditions, the limit of detection of the daptomycin assay was 1 mg/L.

The areas under the concentration–time curve (AUC) of daptomycin in either plasma or tissue cage fluid were estimated by the linear trapezoidal rule from 0–24 h (AUC₀–₂₄) on days 4 and 7 of administration of this antimicrobial agent.

Results

In vitro studies

The MIC and MBC of daptomycin in CSMBH were 1–2 and 2–4 mg/L, respectively, for strain Rev1; the MIC and MBC of daptomycin in the presence of 50% tissue cage fluid added to CSMBH were 2 and 4 mg/L, respectively, for strain Rev1; the MIC and MBC of vancomycin in CAMHB were 1 and 2 mg/L, respectively, for strain Rev1.

Time–kill studies performed in CSMBH showed rapid elimination of exponential-phase cultures of strain Rev1 by daptomycin 4 mg/L. The reduction in the viable counts of strain Rev1 by daptomycin exceeded 3 log₁₀ cfu/mL after 3 h (data not shown). A similar reduction in the viable counts of strain Rev1 by daptomycin 4 mg/L was observed in CSMBH supplemented with 50% tissue cage fluid (data not shown).

Pharmacokinetics of antimicrobial agents in tissue cage fluid

At day 4 of therapy, the mean levels of daptomycin in tissue cage fluids (n = 6) of animals treated with daptomycin were 5.4 at time zero, 6.6 at 2 h, 9.8 at 4 h, 11.8 at 6 h, 10.0 at 12 h and 3.4 mg/L at 24 h, respectively, after administration of a 30 mg/kg once-daily regimen (Figure 1). Similar concentrations of daptomycin were recorded at day 7 of therapy (data not shown). Since residual levels of daptomycin were nearly equivalent to the MBC of this antimicrobial agent for strain Rev1, recorded in CSMBH containing 50% tissue cage fluid, the daptomycin once-daily regimen yielded bactericidal levels of daptomycin in infected tissue cage fluids throughout therapy. At day 4 of therapy, the tissue cage fluid AUC₀–₂₄ of daptomycin was 195.8 mg h/L.

In comparison, blood levels of animals treated with a 30 mg/kg intraperitoneal regimen of daptomycin showed a C_max of 141 mg/L at 1 h, and a concentration of 8.2 mg/L at 8 h. The trough level was 0, which differs from human pharmacokinetics in which daptomycin maintains trough levels of 1–9 mg/L. The AUC₀–₂₄ of daptomycin was 558 mg h/L, which is only slightly higher than the clinical AUC₀–₂₄ of 468 mg h/L.44

Figure 1. Pharmacokinetic levels of daptomycin in plasma, and tissue cage fluids of rats on day 4 of therapy with 30 mg/kg once-daily dosing.
The average peak and trough tissue cage fluid levels of vancomycin determined in a previous study \(^{34}\) were 12 and 2 mg/L at 4 and 12 h, respectively.

**Treatment of chronic tissue cage infections**

At the onset of therapy, average bacterial counts for cages infected with strain Rev1 were 6.87 ± 0.28 cfu/mL for controls \((n = 24)\), 6.25 ± 0.17 log\(_{10}\) cfu/mL for animals receiving daptomycin once a day \((n = 28)\), and 6.43 ± 0.13 log\(_{10}\) cfu/mL for animals receiving vancomycin twice a day \((n = 35)\). At the end of the 7 day treatment period, bacterial counts in the tissue cages of control animals showed a slight and non-significant increase of 0.24 ± 0.23 log\(_{10}\) cfu/mL \((n = 24)\). In contrast, both the daptomycin and vancomycin regimens (Figure 2) led to significant reductions in bacterial counts in tissue cage fluids of 1.11 ± 0.25 \((n = 28; P = 0.001)\) and 0.80 ± 0.31 log\(_{10}\) cfu/mL \((n = 35; P = 0.02)\), respectively, compared with tissue cage fluids of control animals. The higher average reduction in cfu counts of rats treated with daptomycin compared with that of vancomycin-treated animals did not reach statistical significance \((P = 0.45)\).

**Comparison of daptomycin activity on bacteria grown in vitro and in vivo**

To evaluate the bactericidal activity of daptomycin compared with vancomycin against tissue cage fluid organisms of strain Rev1 in conditions relevant to therapy, we assayed, in parallel, the elimination rates of tissue cage and *in vitro* grown bacteria by 4 mg/L of either antimicrobial agent in the presence of 50% sterile tissue cage fluid in CSMHB. Stationary-phase were preferred to log-phase organisms to make the comparison with *ex vivo* bacteria more relevant. \(^{35,38}\) Figure 3 shows a significantly \((P<0.001)\) higher elimination rate of stationary-phase organisms by daptomycin 4 mg/L, compared with vancomycin, during the initial 4 h period of drug exposure, which led to 3 log\(_{10}\) reductions in viable counts at 4 versus 6 h, respectively. However, the most impressive differences in the bactericidal activities of daptomycin compared with vancomycin were seen with bacteria freshly removed from infected cages. During the initial 6 h period of drug exposure, the average reductions in viable counts of tissue cage bacteria by daptomycin 4 mg/L were 2.1 and 2.6 log\(_{10}\) cfu/mL at 4 and 6 h, respectively, compared with 0.3 and 0.6 log\(_{10}\) cfu/mL with vancomycin 4 mg/L (Figure 3). The presence of 50% tissue cage fluid, yielding average protein concentrations of 0.17 log\(_{10}\) cfu/mL for animals receiving daptomycin once a day and 0.3 log\(_{10}\) cfu/mL at day 8 were 5.05 ± 0.25 log\(_{10}\) cfu/mL. In contrast, three of the 22 cages whose average viable counts \(6.86 ± 0.13 \log_{10}\) cfu/mL \(× 10^4\) The number of colonies that grew on daptomycin-supplemented MHA from these three cages were 6, 23 and 31 cfu, respectively, yielding an average concentration of \(3.21 ± 0.21 \log_{10}\) cfu/mL. Phenotypical properties (haemolysis, coagulase) and the PFGE pattern of the bacteria grown on daptomycin-supplemented MHA were identical to those of the parental strain Rev1. Further studies of daptomycin resistance phenotypes were performed with the two cages yielding the highest concentrations.
viable counts (>20 cfu per plate) of daptomycin-supplemented MHA.

The stability and homogeneity of the daptomycin resistance phenotypes were evaluated on 10 colonies randomly selected from each daptomycin-supplemented primary plate. We compared their overall antimicrobial susceptibility with that of strain Rev1, using disc diffusion on MHA. Each daptomycin-selected colony exhibited a consistent 3–4 mm reduction in zone sizes around the daptomycin discs (19–20 mm) compared with those recorded around the parental strain Rev1 (23 mm). In contrast, all other zone sizes around 15 additional antibiotic discs were identical for all daptomycin-selected colonies and Rev1, which further confirmed their respective clonal identity.

The resistance phenotypes of six daptomycin-selected colonies were found to be stable after 1 year of storage at −70°C, since the viable counts of all subclones on MHA supplemented with daptomycin 4 mg/L were nearly equivalent to those enumerated on antibiotic-free MHA. In contrast, the cfu counts of strain Rev1 plated on the same daptomycin-containing MHA medium represented only 103 of those on daptomycin-free MHA, thus confirming the low spontaneous emergence of daptomycin resistance in the parental strain.

When tested by the broth microdilution or macrodilution methods in CAMHB adjusted to 50 mg/L Ca++ or non-adjusted, daptomycin-selected colonies showed average 4-fold and 8-fold increases in daptomycin MICs, respectively, compared with strain Rev1. Similar values were found after 1 year of storage at −70°C, or after repeated passages in daptomycin-free MHB (data not shown).

**Discussion**

Establishment of an optimal dosing of daptomycin for the safe and effective treatment of serious Gram-positive infections, in particular those resistant to multiple antibiotics, would represent an important therapeutic achievement. The rapid *in vitro* bactericidal activity of daptomycin, combined with its low potential for *in vitro* spontaneous acquisition of antibiotic resistance22 and absence of cross-resistance with other antimicrobial agents, represent attractive properties for targeting microbial organisms involved in chronic or foreign body infections. Many of the early animal studies conducted in the 1980s and early 1990s indeed showed daptomycin’s efficacy in deep-seated infections, such as endocarditis,20,31,32 but did not define optimal pharmacokinetic and pharmacodynamic properties for this antibiotic that might be of direct use for currently performed human trials. Another frequently mentioned problem associated with daptomycin *in vitro* testing is the requirement of well-characterized microbiological media, with well-adjusted contents of ionized calcium, to obtain reliable *in vitro* data on daptomycin susceptibility or resistance in staphylococci and enterococci.17,21,22 The lack of properly labelled information on the cation content on a number of commercially available liquid and solid media might be the source of significant errors in susceptibility testing of staphylococcal and enterococcal clinical isolates.

A useful property of subcutaneous tissue cage models of implant-associated infections due to *S. aureus*34–37,39 or *Staphylococcus epidermidis*45,46 is the possibility of the direct assessment of the levels of each antimicrobial agent in tissue cage fluids. This allows direct estimates to be made of the tissue cage concentration–time profile of each antimicrobial agent in tissue cage fluids. In recent years, pharmacodynamic modelling of the therapeutic efficacies of antimicrobial agents has been developed, and is a powerful tool that combines the pharmacokinetic properties of each agent with the antimicrobial susceptibilities of their microbial targets.47,48 These pharmacodynamic concepts were applied recently to daptomycin in a murine thigh model of *S. aureus* infection, which indicated that the plasma AUC/MIC ratio was an important predictor of successful microbiological outcome.28 The plasma AUC0–24 of daptomycin recorded in our tissue cage rat model (which was slightly higher than the average AUC0–24 of human volunteers receiving a clinical dose of 4 mg/kg)24 falls within the AUC0–24 values leading to bactericidal activities in the murine thigh *S. aureus* infection model.28 Despite being 65% lower than that recorded in rat plasma, the tissue cage fluid AUC0–24 of daptomycin was still sufficient to exert a significant bactericidal effect in the locally infected cage fluids, even against strain Rev1. The efficacy of daptomycin, compared with that of several other antimicrobial agents tested in the hard-to-treat rat model of chronic foreign body infection,34–39 was at least equivalent to a larger daily regimen of vancomycin, and is an indication for its good bactericidal activity *in vivo*. This assumption was confirmed by *in vitro* testing demonstrating bactericidal activity of daptomycin at 4 mg/L, equivalent to its MBC against strain Rev1. Daptomycin is ~90% bound by serum proteins.42 However, *in vitro* testing indicated that the presence of tissue cage fluid components, which contain serum-derived proteins, did not significantly affect the bactericidal activity of daptomycin at a concentration of 4 mg/L against organisms, collected from either a stationary-phase culture or even freshly removed from infected cage fluids.

**Tissue cage grown bacteria frequently express in vivo-induced tolerance to different antibiotics.30,33,42** This *in vivo* induced tolerance, which is either not expressed or rapidly disappears under *in vitro* conditions, is referred to as phenotypical tolerance.43 In contrast to the previously described high level of phenotypical tolerance expressed by tissue cage bacteria against teicoplanin,35 daptomycin still demonstrates a high level of bactericidal activity against the potentially tolerant bacteria.

Since the relatively low concentrations of daptomycin reached in the chronically infected cage fluids, varying only from the MBC to three times the MBC levels, already showed therapeutic efficacy, these data suggest that optimization of the pharmacokinetic and pharmacodynamic parameters to this particular infection model potentially might lead to significantly improved therapeutic responses by reaching higher local levels of daptomycin, as suggested by a recent preliminary report.50

The emergence, in three infected cages, of subpopulations exhibiting decreased susceptibility to daptomycin, compared with the parental strain Rev1, was an interesting microbiological finding whose real clinical significance is still uncertain. A single previous study mentioned the emergence of *S. aureus* subpopulations exhibiting diminished susceptibility during daptomycin therapy of experimental endocarditis in rabbits.31 These rabbits were treated with suboptimal dosages of daptomycin, which yielded isolates with an increase in MIC value in 13% of rabbits. Trough levels of daptomycin in tissue cage fluid were just equivalent to the MBC for strain Rev1. Animal-to-animal variability cannot exclude that daptomycin levels fell below the MBC in these three rats, allowing emergence of resistant subpopulations.

In conclusion, daptomycin showed an encouraging *in vivo* efficacy in the rat model of chronic foreign body infections due to *S. aureus* Rev1, and was equivalent to that of vancomycin. Daptomycin produced significant reductions in the bacterial burden of *S. aureus*. High tissue levels of daptomycin seem to be required to minimize emergence of subpopulations exhibiting decreased susceptibility to daptomycin. Prediction of the therapeutic efficacies of var-
ious antibiotics against foreign body infections may be difficult by relying exclusively on in vitro pharmacodynamic models derived from pharmacokinetic data in the plasma compartment. Our data further emphasize the value of performing experiments in animals for the primary evaluation of new therapeutic agents.

Acknowledgements

We thank Manuela Bento for technical assistance, and Dr Jeff Alder, Megan Robertson, Jared Silverman and Changfu Cheng for yielding the plasma pharmacokinetic data and providing help in manuscript preparation.

This work was supported in part by research grant from Cubist Pharmaceuticals, Inc., Lexington, Mass., and grants 4049–063250, 3200–63710.00 (to P.V.) and 632–57950.99 (to J.S.) from the Swiss National Science Foundation.

References

34. Lucet, J. C., Herrmann, M., Rohner, P. et al. (1990). Treatment of experimental foreign body infection caused by methicillin-resistant
Daptomycin in staphylococcal foreign body infection


